Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesWeekly paclitaxel and cisplatin in the treatment of elderly advanced non-small cell lung cancer
Chinese Journal of Lung Cancer, 10/27/09
LIANG Y et al. – The patients of advanced NSCLC more than 70 years old can tolerate weekly paclitaxel and cisplatin and can get benefit from this regiment.
Methods- 50 chemotherapy-naïve patients with advanced NSCLC
- > 70 years old
- Administrated weekly paclitaxel and pisplatin regiment: PTX 80 mg/m2 intravenous infusion for 1 h, d1, d8 (given routine premedications before PTX), DDP 20 mg/m2 intravenous infusion, d1, d8, every 21 days
- 50 patients were enrolled, and 48 patients were evaluable for response
- ORR (overall response rate) 39.6%
- Median survival time (MST) 14.8 months
- 1 year survival rate 58.3%
- Most common adverse events were leucopenia (60%), anemia (62%), nausea and vomiting (30%), alopecia (100%)
- No chemotherapy-related deaths
Related Articles
Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer
Pathology International, 10/30/09
Relevance Score: 79%
Results of a preliminary study using hypofractionated involved-field radiation therapy and concurrent carboplatin/paclitaxel in the treatment of locally advanced non-small-cell lung cancer
International Journal of Clinical Oncology, 10/30/09
Relevance Score: 79%
Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer
Annals of Oncology, 10/20/09
Relevance Score: 79%
Lung cancer: a biologically different disease in women?
Women's Health, 10/30/09
Relevance Score: 68%
A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic NSCLC
Annals of Oncology, 10/19/09
Relevance Score: 68%
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Enhanced activity of the CREB co-activator Crtc1 in LKB1 null lung cancer
Oncogene, 12/16/09
The promyelocytic leukemia zinc-finger gene, PLZF, is frequently downregulated in malignant mesothelioma cells and contributes to cell survival
Oncogene, 12/16/09
IMP3 expression is correlated with histologic grade of lung adenocarcinoma
Human Pathology, 12/16/09
Sponsor
Article Search
Sponsor
Sponsor